Helio Genomics Collaborates with University of California, Irvine, to Study Effectiveness of Multimodal Epigenetic Sequencing for Enhancing Early Cancer Detection
18 Jan 2024
Clinical Study
Findings published in open-access journal Genome Medicine.
IRVINE, Calif., Jan. 18, 2024 /PRNewswire/ -- Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced that results from an important new research study have been published in the peer-reviewed journal, Genome Medicine.
The study is entitled "Multimodal Epigenetic Sequencing Analysis (MESA) of Cell-free DNA for Non-invasive Colorectal Cancer Detection." This study was conducted as a collaboration between Helio Genomics, its sister company and the Division of Computational Biomedicine at the University of California, Irvine.
"We are excited to partner with Helio Genomics in the development of MESA, a groundbreaking innovation in liquid biopsy technology that promises to transform the early detection and management of numerous human diseases," said Dr. Wei Li, the division's Grace B. Bell Endowed Chair and Professor of Bioinformatics.
Applied to 690 cell-free DNA (cfDNA) samples from three colorectal cancer clinical cohorts, the novel MESA approach improved cancer detection when compared to traditional approaches that use epigenetic markers of promoter DNA methylation.
Key results of the study included:
The MESA approach successfully captured both cfDNA methylation features and nucleosome organization information within a single assay.
cfDNA methylation data captured in the MESA approach enabled detection of colorectal cancer.
Nucleosome organization information (Nucleosome occupancy and fuzziness) captured by the MESA approach also enabled detection of colorectal cancer.
Integrating multimodal epigenetic features (cfDNA methylation, nucleosome occupancy, nucleosome fuzziness, and a window protection score as a measure of nucleosome positioning) by using MESA enhanced cancer detection when compared to any single modality alone.
MESA was shown to be effective in multiple cohorts of patients, demonstrating the robustness of this multimodal approach.
A significant advantage of MESA is its ability to effectively combine four highly complementary epigenetic modalities: cfDNA methylation, nucleosome occupancy, nucleosome fuzziness, and a window protection score (WPS) as a measure of nucleosome positioning across gene promoters and polyadenylation sites.
The study found that MESA, by integrating these multiple epigenetic modalities, demonstrated superior accuracy for the detection of colorectal, liver and pancreatic cancers compared to models based on a single modality. As a result, MESA represents a major advancement in non-invasive cancer detection by leveraging comprehensive and complementary epigenetic profiles of cfDNA within a single assay.
The underlying discovery that methylation features, nucleosome organization features and fragmentation features can be combined to generate superior models is also the subject of U.S. and international patent applications.
"With the combination of Helio's high throughput ECLIPSE platform for data collection and the MESA approach for data analysis, Helio is now in a remarkable position to not only identify many different features of cfDNA that are indicative of disease, but also to develop better models to identify early disease," noted David Taggart, Chief Science Officer for Helio Geonomics. "These two advances will ultimately benefit patients through the development of more accurate, easy to use diagnostic tests that can detect cancers early, when more treatment options are available and curative treatment is more likely."
Helio has also developed the HelioLiver test, a multi-analyte blood test designed to aid in the detection of liver cancers. MESA offers a flexible and sensitive approach to capturing and integrating a diverse range of epigenetic features in cell-free DNA (cfDNA) using a single experimental assay.
Read the MESA study report here:
https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-023-01280-6
For information on Helio Genomics and its innovative solutions for early cancer detection, visit www.heliogenomics.com.
About Helio Genomics
Founded in 2016 and headquartered in Irvine, California, Helio Genomics is a cancer diagnostics technology and test developer. The company focuses on creating and advancing cutting-edge AI-enabled technologies to detect and screen for cancer at its earliest stage, including liver and colon cancer. To learn more, please visit https://heliogenomics.com/.
IMAGE DOWNLOAD - http://www.kcomm.com/wp-content/uploads/2024/01/helio-genomics-logo.jpeg
IMAGE CAPTION - Helio Genomics logo
SOURCE Helio Genomics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.